WGS

GeneDx Holdings Corp.
NASDAQHEALTHCAREDIAGNOSTICS & RESEARCH

Key Statistics

Market Cap
$1.84B
P/E Ratio
EPS
$-2.72
Beta
1.91
52W High
$170.87
52W Low
$32.21
50-Day MA
$58.54
200-Day MA
$91.90
Dividend Yield
Profit Margin
-17.60%
Forward P/E
204.08
PEG Ratio

About GeneDx Holdings Corp.

Sema4 Holdings Corp. The company is headquartered in Stamford, Connecticut.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$442.68M
Gross Profit (TTM)$307.91M
EBITDA$-7.85M
Operating Margin-25.60%
Return on Equity-30.40%
Return on Assets-4.37%
Revenue/Share (TTM)$15.30
Book Value$8.57
Price-to-Book7.08
Price-to-Sales (TTM)4.15
EV/Revenue4.06
EV/EBITDA161.17
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)17.40%
Shares Outstanding$29.69M
Float$18.94M
% Insiders12.30%
% Institutions115.41%

Historical Volatility

HV 10-Day
HV 20-Day
HV 30-Day
HV 60-Day
HV Rank

Analyst Ratings

Consensus ($81.78 target)
1
Strong Buy
8
Buy

Latest News

WGS DEADLINE ALERT: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- August 3, 2026 Deadline

SAN FRANCISCO, July 29, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in GeneDx Holdings Corp. (NASDAQ: WGS) that a securities fraud class action lawsuit has been filed, and the firm is actively urging investors with substantial losses contact the firm now. The upcoming lead plaintiff deadline is August 3, 2026.

PRNewsWire7/29/2026Neutral
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GeneDx securities between April 16, 2025 and May 4, 2026, both dates inclusive (the “Class Period”).

GlobeNewsWire7/29/2026Neutral
HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline

SAN FRANCISCO, July 29, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in GeneDx Holdings Corp. (NASDAQ: WGS) that a securities fraud class action lawsuit has been filed, and the firm is actively urging investors with substantial losses contact the firm now. The upcoming lead plaintiff deadline is August 3, 2026.

PRNewsWire7/29/2026Neutral
Levi & Korsinsky Reminds GeneDx Holdings Corp. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 3, 2026 - WGS

Time-Sensitive: Allegations Focus on Deteriorating Reimbursement Rates and Margin Compression Concealed From GeneDx Investors NEW YORK, July 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in GeneDx Holdings Corp. (NASDAQ: WGS) of a pending securities class action. Class Period: April 16, 2025 through May 4, 2026.

PRNewsWire7/29/2026Neutral
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK and NEW ORLEANS, July 28, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NasdaqGS: WGS) (“GeneDx” or the “Company”), if they purchased or otherwise acquired the Company's shares between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”).

GlobeNewsWire7/29/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GeneDx Holdings Corp. of Class Action Lawsuit and Upcoming Deadlines – WGS

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS).   Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

GlobeNewsWire7/28/2026Neutral
WGS 6-DAY DEADLINE ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline

SAN FRANCISCO, July 28, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in GeneDx Holdings Corp. (NASDAQ: WGS) that a securities fraud class action lawsuit has been filed, and the firm is actively urging investors with substantial losses contact the firm now. The upcoming lead plaintiff deadline is August 3, 2026.

GlobeNewsWire7/28/2026Neutral
WGS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important August 3 Deadline in Securities Class Action - WGS

New York, New York--(Newsfile Corp. - July 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 3, 2026 lead plaintiff deadline. SO WHAT: If you purchased GeneDx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp7/28/2026Neutral
Portnoy Law Firm Announces Class Action on Behalf of GeneDX Holdings, Corp. Investors

LOS ANGELES, July 28, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises GeneDX Holdings, Corp., (“GeneDX” or the "Company") (NASDAQ: WGS) investors of a class action on behalf of investors that bought securities between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”). GeneDX investors have until August 3, 2026 to file a lead plaintiff motion.

GlobeNewsWire7/28/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on WGS and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 7/29/2026